Latest Glycopeptide antibiotics Stories
VIENNA and PHILADELPHIA, January 29, 2015 /PRNewswire/ -- Charles Rowland joins Supervisory Board Dr Steven Gelone
Debio 1450, oral/IV FabI inhibitor active against all Staphylococcus species has received fast track designation for ABSSSI (acute bacterial skin and skin structure infections) LAUSANNE, Switzerland,
On October 8, the FDA announced that one lot of Vancomycin Hydrochloride for Injection, USP, by Hospira Inc., is recalled due to uncontrolled storage during transit.
Topical report “Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2014” worked out by Global Markets Direct is now available at MarketPublishers.com.
Company Completes Enrollment in Phase 2 Clinical Trial AUSTIN, Texas, Oct.
Data demonstrate potent, broad spectrum activity against gram-positive and gram-negative bacteria, including resistant organisms that cause skin infections NEW YORK, Sept.
VIENNA, September 3, 2014 /PRNewswire/ -- New US Subsidiary to be located in the Philadelphia Area Nabriva Therapeutics AG, a biotechnology
To Effectively Compete with Current Anti-MRSA Therapies, Emerging Agents Will Need to be Amenable to Outpatient Use, According to Findings from Decision Resources Group BURLINGTON, Mass., July
Two separate studies published this week in the New England Journal of Medicine are paving the way for more effective treatments in deadly methicillin-resistant Staphylococcus aureus (MRSA) infections.
Lipoglycopeptides Dalvance and Oritavancin Will Find Favorable Uptake as Convenient Outpatient Anti-MRSA Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., April
- The word or words serving to define another word or expression, as in a dictionary entry.